Symptomatic CNS metastases OR superior vena cava (SVC) syndrome OR rapid radiographic pro...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-NSCLC-TRANSFORMATION-PROGRESSION |
|---|---|
| Type | Red flag |
| Status | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Red Flag Origin
| Definition | Symptomatic CNS metastases OR superior vena cava (SVC) syndrome OR rapid radiographic progression on therapy — emergency / aggressive-progression flag requiring brain imaging, RT/surgical consult, and treatment intensification or sequencing change. |
|---|---|
| Clinical direction | hold |
| Category | transformation-progression |
Trigger Logic
{
"any_of": [
{
"finding": "symptomatic_cns_metastases",
"value": true
},
{
"finding": "svc_syndrome",
"value": true
},
{
"finding": "rapid_radiographic_progression_nsclc",
"value": true
}
],
"type": "composite_clinical"
}
Notes
CNS-active TKI options critical for ALK / EGFR / ROS1 mets — alectinib / lorlatinib / brigatinib / osimertinib all have CNS efficacy. SVC syndrome: emergent RT or stenting; systemic therapy proceeds in parallel.
Used By
Algorithms
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L
Indications
IND-NSCLC-3L-DRIVER-BEYOND-2L- IND-NSCLC-3L-DRIVER-BEYOND-2LIND-NSCLC-3L-OSI-FAILURE-AMI- IND-NSCLC-3L-OSI-FAILURE-AMIIND-NSCLC-ALK-MAINT-ALECTINIB- IND-NSCLC-ALK-MAINT-ALECTINIBIND-NSCLC-EGFR-MAINT-OSIMERTINIB- IND-NSCLC-EGFR-MAINT-OSIMERTINIBIND-NSCLC-ELDERLY-CARBO-PEM-MOD- IND-NSCLC-ELDERLY-CARBO-PEM-MOD